Structural genomics and drug discovery: all in the family.
Structural genomics is starting to have an impact on the early stages of drug discovery and target validation through the contribution of new structures of known and potential drug targets, their complexes with ligands and protocols and reagents for additional structural work within a drug discovery program. Recent progress includes structures of targets from bacterial, viral and protozoan human pathogens, and human targets from known or potential druggable protein families such as, kinases, phosphatases, dehydrogenases/oxidoreductases, sulfo-, acetyl- and methyl-transferases, and a number of other key metabolic enzymes. Importantly, many of these structures contained ligands in the active sites, including for example, the first structures of target-bound therapeutics. Structural genomics of protein families combined with ligand discovery holds particular promise for advancing early stage discovery programs.
Weigelt
Johan
J
Structural Genomics Consortium, Karolinska Institutet, MBB/SGC, 171 77 Stockholm, Sweden. johan.weigelt@ki.se
McBroom-Cerajewski
Linda D B
LD
Schapira
Matthieu
M
Zhao
Yong
Y
Arrowsmith
Cheryl H
CH
Arrowmsmith
Cheryl H
CH
D000818:Animals; D001665:Binding Sites; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D023281:Genomics; D006801:Humans; D008024:Ligands; D011506:Proteins / Q000737:chemistry* / Q000378:metabolism*
D008024:Ligands; D011506:Proteins